Today: 21 May 2026
RTX stock price holds near $200 after $1B Army radar contract — what traders are watching next
30 January 2026
2 mins read

RTX stock price holds near $200 after $1B Army radar contract — what traders are watching next

New York, Jan 30, 2026, 14:20 EST — Regular session.

  • RTX shares ticked up after the U.S. Army announced a $1.025 billion contract modification linked to Raytheon’s LTAMDS program.
  • Raytheon’s order flow drew attention again with a separate $197 million award for reconnaissance pods destined for Poland.
  • Traders are balancing contract momentum with delivery schedules and RTX’s earnings report due in late April.

RTX shares ticked up 0.3% to $200.50 Friday afternoon following news that the U.S. Army awarded a $1,025,100,000 contract modification to Raytheon for its Lower Tier Air and Missile Defense Sensor (LTAMDS) program. The work will take place in Andover, with an expected completion date set for March 31, 2030, the announcement states.

Why this matters now: investors aren’t just focused on headline wins—they’re zeroing in on how fast funding flows and deliveries roll out in air-defense programs. Contract updates might seem routine, but they often reveal the production pace and how swiftly backlog converts to revenue.

RTX projected adjusted sales between $92 billion and $93 billion for 2026, along with adjusted earnings per share ranging from $6.60 to $6.80. That follows 2025 sales of $88.6 billion. The company closed 2025 carrying a backlog of $268 billion in undelivered orders. CEO Chris Calio said RTX entered 2026 with “great momentum.” These adjusted numbers exclude items like acquisition-related accounting and restructuring charges. Free cash flow refers to cash remaining after capital expenditures. SEC

Raytheon secured a $197 million deal with the U.S. Air Force Life Cycle Management Center for the MS-110 multispectral reconnaissance system, designated for the Polish Air Force, RTX announced on Jan. 28. Dan Theisen described the MS-110 as delivering “advanced capability by pushing next-generation processing to the tactical edge.” RTX

TTM Technologies announced a multi-year deal with Raytheon to supply radio-frequency assemblies and other hardware, potentially worth $200 million over three years. Raytheon VP Mike Mills said the contract “will allow us to meet our accelerated delivery schedule while reducing costs.” GlobeNewswire

Bernstein bumped its price target on RTX to $204 from $189 but maintained a Market Perform rating, according to MT Newswires.

Defense shares showed a mixed picture. The iShares U.S. Aerospace & Defense ETF (ITA) dipped roughly 0.1%. Lockheed Martin climbed 1.6%, but Northrop Grumman dropped 0.8%. L3Harris Technologies slid 3.2%, while Boeing edged down 0.5%. The broader market pulled back, with the S&P 500 ETF (SPY) falling 0.3% and the Nasdaq 100 ETF (QQQ) losing 0.9%.

Traders are focusing less on the size of individual awards and more on the rhythm — follow-on contract items, obligated funding, and delivery timelines. When those begin to falter, the stock usually reacts.

There are clear risks. Government contracts can be delayed, altered, or repriced, while multi-year programs hinge on budget approvals and timely delivery. Tariffs on metals and persistent supply chain challenges have weighed on the outlook. Management has come under increased Washington scrutiny over capital returns but reassured investors it remains committed to the dividend.

RTX is set to release its first-quarter earnings on April 28. Investors will focus on any updates to the 2026 sales and cash goals, along with new insights into production schedules at Raytheon, Pratt & Whitney, and Collins Aerospace.

Stock Market Today

  • Teradyne, Kulicke and Soffa, Impinj, Microchip, IPG Photonics Stocks Slide on U.S.-China Semiconductor Summit Outcome
    May 21, 2026, 2:58 AM EDT. Shares of Teradyne, Kulicke and Soffa, Impinj, Microchip Technology, and IPG Photonics dropped sharply following the U.S.-China summit, which ended without key breakthroughs on semiconductor exports. Expectations for U.S. approval of Nvidia's H200 chip shipments to China were unmet, disappointing investors. U.S. Trade Representative Jamieson Greer indicated semiconductors were not a negotiation focus, dampening near-term optimism. Despite the sell-off, IPG Photonics' stock, known for volatility, remains down significantly from its 52-week high but has gained 34.3% year-to-date. Market reactions highlight cautious sentiment amid geopolitical tensions, with analysts skeptical about swift comprehensive deals due to national security concerns.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Johnson & Johnson stock today: JNJ steadies after talc court win, EU panel backs AKEEGA expansion
Previous Story

Johnson & Johnson stock today: JNJ steadies after talc court win, EU panel backs AKEEGA expansion

Joby Aviation stock drops again as $1.2 billion capital raise puts dilution back in focus
Next Story

Joby Aviation stock drops again as $1.2 billion capital raise puts dilution back in focus

Go toTop